Alzheimer’s Disease Imaging Guidelines Supported by New Research

With proposed US National Institute on Aging (NIA; Bethesda, MD, USA) and the Alzheimer’s Association (Chicago, IL, USA) guidelines for detecting Alzheimer’s-related brain changes expected in September 2011, these articles give a preview of what may be to come. The studies were both published in the August 2011 issue of the Journal of Nuclear Medicine (JNM).

Earlier in 2011, the NIA and the Alzheimer’s Association released new criteria and guidelines for the diagnosis of Alzheimer’s disease (AD). The new proposed guidelines available the fall of 2011 will offer additional information regarding the development of tests to measure biologic changes in the brain, blood, or spinal fluid to diagnose AD at an earlier stage.

Earlier diagnosis of AD is the focus of the new study, conducted by investigators from the department of medicine, the University of Melbourne (Parkville, Victoria, Australia) in which researchers compared cortical amyloid deposition using ¹⁸F-florbetaben and PET in 109 controls and study participants with mild cognitive impairment (MCI), frontotemporal lobar degeneration, dementia with Lewy bodies, vascular dementia, Parkinson’s disease, and AD. The study’s findings revealed that ¹⁸F-florbetaben performs with the same high accuracy as previously reported with ¹¹C-Pittsburgh compound B--the most specific and widely used amyloid-imaging agent--for differentiating between specific types of neurodegenerative dementia, particularly for diagnosis of AD from frontotemporal dementia.

“The difference between ¹¹C-Pittsburgh compound B and ¹⁸F-florbetaben is that the ¹⁸F-florbetaben has a longer half-life and is more affordable, making it appropriate for clinical use,” said Christopher Rowe, MD, FRACP, one of the authors of the study. “This distinction profoundly affects treatment and prognosis and has genetic implications for the family.”

In addition to detecting AD earlier, molecular imaging can also be used in clinical trials to help develop pharmaceuticals to prevent or delay the onset of dementia. This is particularly of significance to patients with MCI who have yet to develop Alzheimer’s disease.

“We urgently need tools for conducting drug trials for MCI more efficiently,” noted Karl Herholz, MD, lead author of the study, from the University of Manchester (UK). He continued, “Clinical outcome parameters show large variability and little sensitivity to progression at that stage, making these trials extremely costly and cumbersome. By using imaging biomarkers as primary outcome parameters, clinical trials can be performed with smaller sample sizes or shorter trial duration without loss of study power.”

The study evaluated a predefined quantitative measure--a PET score--that was extracted automatically from ¹⁸F-FDG PET scans using a sample of controls, patients with MCI, and patients with Alzheimer’s disease. The PET scores provided a much higher test-retest reliability than standard neuropsychologic test scores (Alzheimer’s Disease Assessment Scale-Cognitive and Mini-Mental State Examination) and superior strength for measuring progression, as well as a valid measurement of cognitive impairment. As such, the PET scores can be considered a valid imaging biomarker to monitor the progression of MCI to Alzheimer's disease.

“Prevention of dementia by drugs applied at MCI stage would greatly improve quality of life for patients and reduce costs of dementia care and treatment. Thus, development of such drugs and efficient tools for testing them are extremely important,” concluded Dr. Herholz.

AD is an irreversible, progressive brain disease that slowly destroys memory and thinking skills, and ultimately, the ability to carry out the simplest tasks of daily living. Although treatment can slow the progression of the disease and help manage its symptoms, there is no cure for Alzheimer’s disease.

Related Links:
University of Melbourne
University of Manchester